Coty Announces Agreement With Kering for Early Transition of Gucci Beauty License
Coty to receive approximately $400 million in consideration for the early termination plus sale of sufficient Gucci Beauty inventory to support the transition Coty to continue operating Gucci
Vect-Horus announces collaboration and license option agreement with Servier to develop targeted oligonucleotide therapeutics for rare CNS diseases
| The Manila Times
Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
| The Manila Times